These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 8319063)

  • 1. Abdominal MRI using a negative contrast agent.
    Bach-Gansmo T; Dupas B; Gayet-Delacroix M; Lambrechts M
    Br J Radiol; 1993 May; 66(785):420-5. PubMed ID: 8319063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III trial of oral magnetic particles in MRI of abdomen and pelvis.
    MacVicar D; Jacobsen TF; Guy R; Husband JE
    Clin Radiol; 1993 Mar; 47(3):183-8. PubMed ID: 8472481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ferrimagnetic susceptibility contrast agents.
    Bach-Gansmo T
    Acta Radiol Suppl; 1993; 387():1-30. PubMed ID: 8390776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral magnetic particles. Results from clinical phase II trials in 216 patients.
    Oksendal AN; Bach-Gansmo T; Jacobsen TF; Eide H; Andrew E
    Acta Radiol; 1993 Mar; 34(2):187-93. PubMed ID: 8452728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of hyoscine butylbromide in abdominal MR imaging with and without oral magnetic particles.
    Laniado M; Grönewäller E; Kopp AF; Kaminsky SF; Hamm B; Jacobsen TF; Claussen CD
    Abdom Imaging; 1997; 22(4):381-8. PubMed ID: 9157855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral magnetic particles in MR imaging of the abdomen and pelvis.
    Rinck PA; Smevik O; Nilsen G; Klepp O; Onsrud M; Oksendal A; Børseth A
    Radiology; 1991 Mar; 178(3):775-9. PubMed ID: 1994417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superparamagnetic particles as gastrointestinal contrast agent in magnetic resonance imaging of lower abdomen.
    Niemi P; Katevuo K; Kormano M; Baksaas I; Bach-Gansmo T; Mäenpää J
    Acta Radiol; 1990 Jul; 31(4):409-11. PubMed ID: 2206698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superparamagnetic particles as an oral contrast agent in abdominal magnetic resonance imaging.
    Oksendal AN; Jacobsen TF; Gundersen HG; Rinck PA; Rummeny E
    Invest Radiol; 1991 Nov; 26 Suppl 1():S67-70; discussion S71. PubMed ID: 1808152
    [No Abstract]   [Full Text] [Related]  

  • 9. Contribution of oral magnetic particles in MR imaging of the abdomen with spin-echo and gradient-echo sequences.
    Boudghène FP; Bach-Gansmo T; Grange JD; Lame S; Nantois C; Wallays C; Bigot JM
    J Magn Reson Imaging; 1993; 3(1):107-12. PubMed ID: 8428075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superparamagnetic particles as oral contrast medium in magnetic resonance imaging of patients with treated ovarian cancer--comparison with plain MRI.
    Prayer L; Stiglbauer R; Kramer J; Wimberger D; Poelzleitner D; Schima W; Kainz C; Koelbl H; Haugen I; Imhof H
    Br J Radiol; 1993 May; 66(785):415-9. PubMed ID: 8319062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic improvement in MRI of gynecological neoplasms.
    Marincek B
    J Belge Radiol; 1996 Feb; 79(1):13-7. PubMed ID: 8647782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study between Gd-DTPA and oral magnetic particles (OMP) as gastrointestinal (GI) contrast agents for MRI of the abdomen.
    Vlahos L; Gouliamos A; Athanasopoulou A; Kotoulas G; Claus W; Hatziioannou A; Kalovidouris A; Papavasiliou C
    Magn Reson Imaging; 1994; 12(5):719-26. PubMed ID: 7934658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral superparamagnetic contrast agent (ferumoxsil): tolerance and efficacy in MR imaging of gynecologic diseases.
    Haldemann Heusler RC; Wight E; Marincek B
    J Magn Reson Imaging; 1995; 5(4):385-91. PubMed ID: 7549199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of and sequence choice for two oral contrast agents used during MR imaging.
    Grubnic S; Padhani AR; Revell PB; Husband JE
    AJR Am J Roentgenol; 1999 Jul; 173(1):173-8. PubMed ID: 10397122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The endorem tolerance profile].
    Laniado M; Chachuat A
    Radiologe; 1995 Nov; 35(11 Suppl 2):S266-70. PubMed ID: 8588033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MR imaging of lymph nodes in patients with primary abdominal and pelvic malignancies using ultrasmall superparamagnetic iron oxide (Combidex).
    Harisinghani MG; Saini S; Hahn PF; Weissleder R; Mueller PR
    Acad Radiol; 1998 Apr; 5 Suppl 1():S167-9, discussion S183-4. PubMed ID: 9561072
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral superparamagnetic particles for magnetic resonance imaging. Effect in plain and viscous aqueous suspensions.
    Lönnemark M; Hemmingsson A; Ericsson A; Gundersen HG; Bach-Gansmo T
    Acta Radiol; 1990 May; 31(3):303-7. PubMed ID: 2386643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary results of MR imaging with superparamagnetic iron oxide in pancreatic and retroperitoneal disorders.
    Torres GM; Erquiaga E; Ros PR; Burton SS; Barreda R; Langmo LS; Kennedy SJ
    Radiographics; 1991 Sep; 11(5):785-91; discussion 792-3. PubMed ID: 1947314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodistribution and toxicity of MR imaging contrast media.
    Oksendal AN; Hals PA
    J Magn Reson Imaging; 1993; 3(1):157-65. PubMed ID: 8428083
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety profile of ultrasmall superparamagnetic iron oxide ferumoxtran-10: phase II clinical trial data.
    Sharma R; Saini S; Ros PR; Hahn PF; Small WC; de Lange EE; Stillman AE; Edelman RR; Runge VM; Outwater EK; Morris M; Lucas M
    J Magn Reson Imaging; 1999 Feb; 9(2):291-4. PubMed ID: 10077027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.